Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2017 16:05 ET | Source: REGENXBIO Inc.

REGENXBIO to Participate in the Piper Jaffray GenomeRx Symposium

ROCKVILLE, Md., July 06, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
June 07, 2017 16:01 ET | Source: REGENXBIO Inc.

REGENXBIO and AveXis Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector

ROCKVILLE, Md. and CHICAGO, Ill., June 07, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (NASDAQ:RGNX) and AveXis, Inc. (NASDAQ:AVXS) today announced an exclusive worldwide license agreement for AveXis to...
May 31, 2017 07:00 ET | Source: REGENXBIO Inc.

REGENXBIO Announces Initiation of Phase I Clinical Trial of RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration

Clinical trial evaluates one-time treatment for wet AMD using NAV® AAV8 gene therapy; interim trial update expected late 2017 ROCKVILLE, Md., May 31, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc....
May 10, 2017 16:05 ET | Source: REGENXBIO Inc.

REGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference

ROCKVILLE, Md., May 10, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
May 09, 2017 16:01 ET | Source: REGENXBIO Inc.

REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights

On track to initiate dosing of patients in RGX-314 Phase I trial for wet AMD by mid-2017 and continuing enrollment of patients in RGX-501 Phase I/II trial for HoFHInterim trial updates for RGX-314 and...
May 04, 2017 16:06 ET | Source: REGENXBIO Inc.

Preclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be Presented at Upcoming Conferences

Preclinical data for RGX-314 program for the treatment of wet AMD to be presented at the Retinal Cell and Gene Therapy Innovation Summit, the Association for Research in Vision and Ophthalmology, and...
May 02, 2017 16:05 ET | Source: REGENXBIO Inc.

REGENXBIO to Host Conference Call on May 9 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., May 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
April 26, 2017 16:01 ET | Source: REGENXBIO Inc.

REGENXBIO Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

ROCKVILLE, Md., April 26, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene...
March 28, 2017 07:00 ET | Source: REGENXBIO Inc.

REGENXBIO Enhances and Expands Scientific Leadership

ROCKVILLE, Md., March 28, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene...
March 21, 2017 21:30 ET | Source: REGENXBIO Inc.

REGENXBIO Announces Pricing of Public Offering of Common Stock

ROCKVILLE, Md., March 21, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene...